Chimerix, Inc.

NasdaqGM:CMRX Stock Report

Market Cap: US$268.9m

Chimerix Future Growth

Future criteria checks 2/6

Chimerix is forecast to grow earnings and revenue by 51.7% and 75.2% per annum respectively while EPS is expected to grow by 52% per annum.

Key information

51.7%

Earnings growth rate

52.0%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate75.2%
Future return on equityn/a
Analyst coverage

Low

Last updated11 Dec 2024

Recent future growth updates

Recent updates

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Dec 11

We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

Jul 16
We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Aug 23

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Jul 20
Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Chimerix: Down But Not Out

Jun 06

Chimerix: Searching For Clarity

Jan 05

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Dec 24
Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Sep 16
Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Jun 08
Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Chimerix gets FDA approval for TEMBEXA for the treatment of smallpox

Jun 04

Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

May 13
Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

Chimerix Investor Presentation - Slideshow

May 08

Chimerix expands oncology program with acquisition of Oncoceutics, shares up 10%

Jan 08

Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?

Jan 01
Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?

Chimerix rises 9.1% premarket after FDA accepts NDA for smallpox countermeasure

Dec 07

Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans

Dec 05
Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans

Earnings and Revenue Growth Forecasts

NasdaqGM:CMRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202642-75-80-885
12/31/20254-100-94-1075
12/31/20241-89-94-755
9/30/20240-84-70-70N/A
6/30/20240-85-68-68N/A
3/31/20240-83-64-64N/A
12/31/20230-82-69-69N/A
9/30/20231-85-75-74N/A
6/30/202334180-50-49N/A
3/31/202334176-46-46N/A
12/31/202234172-47-47N/A
9/30/202233154-61-61N/A
6/30/20221-106-83-83N/A
3/31/20221-101-86-85N/A
12/31/20212-173-100-100N/A
9/30/20213-145-75-75N/A
6/30/20215-138-68-68N/A
3/31/20216-131-63-63N/A
12/31/20205-44-36-36N/A
9/30/202011-35-31-30N/A
6/30/202011-98-64-64N/A
3/31/202011-105-70-70N/A
12/31/201913-113-75-75N/A
9/30/201911-124-80-80N/A
6/30/20199-66-51-51N/A
3/31/20199-67-51-51N/A
12/31/20187-69-54-54N/A
9/30/20184-74-58-58N/A
6/30/20185-75N/A-56N/A
3/31/20184-73N/A-55N/A
12/31/20174-71N/A-50N/A
9/30/20175-67N/A-48N/A
6/30/20174-66N/A-49N/A
3/31/20176-68N/A-49N/A
12/31/20166-76N/A-64N/A
9/30/20167-99N/A-87N/A
6/30/20168-115N/A-99N/A
3/31/201611-121N/A-110N/A
12/31/201511-117N/A-100N/A
9/30/20159-100N/A-84N/A
6/30/20158-84N/A-70N/A
3/31/20154-71N/A-57N/A
12/31/20144-59N/A-47N/A
9/30/20144-47N/A-37N/A
6/30/20143-37N/A-31N/A
3/31/20143-46N/A-29N/A
12/31/20134-71N/A-26N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CMRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CMRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CMRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CMRX's revenue (75.2% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: CMRX's revenue (75.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CMRX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:55
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chimerix, Inc. is covered by 22 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBarclays
Jonathan AschoffBrean Capital
Ritu BaralCanaccord Genuity